Q BioMed Inc. (OTCMKTS:QBIO) Short Interest Update
Q BioMed Inc. (OTCMKTS:QBIO) Short Interest Update
Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) was the recipient of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 23,000 shares, a drop of 64.2% from the September 15th total of 64,300 shares. Based on an average daily volume of 1,093,500 shares, the short-interest ratio is currently 0.0 days.
Q BioMed Inc.(場外交易代碼：QBIO-GET Rating)是9月份空頭股數價格大幅下降的接受者。截至9月30日，空頭股數共有2.3萬股，較9月15日的6.43萬股下降了64.2%。以日均成交量1,093,500股計算，短息比率目前為0.0天。
Q BioMed Stock Performance
Q BioMed股票表現
Q BioMed stock remained flat at $0.01 during midday trading on Thursday. 724,212 shares of the company were exchanged, compared to its average volume of 491,000. The firm has a fifty day moving average of $0.03 and a two-hundred day moving average of $0.09. Q BioMed has a 1 year low of $0.01 and a 1 year high of $0.66.
在週四午盤交易中，Q BioMed的股價持平於0.01美元。該公司的股票成交量為724,212股，而平均成交量為491,000股。該公司的50日移動均線切入位在0.03美元，200日移動均線切入位在0.09美元。Q BioMed的一年低點為0.01美元，一年高位為0.66美元。
Q BioMed (OTCMKTS:QBIO – Get Rating) last posted its quarterly earnings data on Thursday, July 28th. The company reported ($0.06) EPS for the quarter. The company had revenue of $0.17 million for the quarter.
Q BioMed(OTCMKTS：QBIO-GET Rating)最近一次公佈季度收益數據是在7月28日星期四。該公司公佈了該季度每股收益(0.06美元)。該公司本季度的收入為17萬美元。
About Q BioMed
關於Q BioMed
Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.
Q BioMed Inc.是一家生物醫學加速和開發公司，專注於許可、收購和向生命科學和醫療保健公司提供資源。該公司提供氯化鍶SR89和美沙酮，這是一種治療轉移性骨癌疼痛的放射性藥物。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Q BioMed (QBIO)
- Domino's Pizza Rises To The Occasion In Q3
- Constellation Brands Stock May Offer Safety in the Market Storm
- Amgen Shares Leap Higher On Upbeat Outlook For Obesity Treatment
- O'Reilly & AutoZone Outperform The S&P: Is Either A Better Stock?
- Three Dividend Growers the Institutions Are Buying
- 免費獲取有關Q BioMed(QBIO)的StockNews.com研究報告
- 多米諾披薩在第三季度應運而生
- 星座品牌股票可能在市場風暴中提供安全
- 安進股價跳漲，肥胖治療前景樂觀
- O‘Reilly&AutoZone的表現好於標準普爾指數：哪隻股票更好？
- 這些機構正在收購的三家股息增長公司
Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
接受Q BioMed Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Q BioMed和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。